Jinlian Xie
138 TongZiPo Road
Changsha, 410013, China
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.
Journal: Expert opinion on investigational drugs
Published: June 08, 2026
A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects.
Journal: Frontiers in pharmacology
Published: March 03, 2026
A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity.
Journal: Diabetes, obesity & metabolism
Published: February 10, 2026
Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.
Journal: Antimicrobial agents and chemotherapy
Published: November 06, 2025
Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study.
Journal: European journal of pharmacology
Published: September 02, 2025
Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects.
Journal: Clinical and experimental medicine
Published: September 01, 2025
Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database.
Journal: Multiple sclerosis and related disorders
Published: June 18, 2025
Safety, tolerability, and pharmacokinetics of 4-fluoroetomidate (NH600001) in healthy subjects: a first-in-human, randomised, controlled, phase I study.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: February 09, 2025
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: August 30, 2024
Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study.
Journal: Antimicrobial agents and chemotherapy
Published: June 20, 2024
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects.
Journal: Drug design, development and therapy
Published: April 26, 2023
Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: July 08, 2020
Last Updated: 09/26/2026